Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study

JOURNAL ARTICLE published July 2022 in Cancer Immunology, Immunotherapy

Authors: Geoffroy Bilger | Nicolas Girard | Hélène Doubre | Matteo Giaj Levra | Etienne Giroux-Leprieur | Frederique Giraud | Chantal Decroisette | Matthieu Carton | Marie Ange Massiani